Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud related to misleading statements made to investors during a specified Class Period [1][2]. Group 1: Investigation Details - Berger Montague is investigating whether Hims & Hers violated federal securities laws by making false or misleading statements during the Class Period from April 29, 2025, to June 22, 2025 [1]. - Following the termination of a partnership with Novo Nordisk due to unauthorized marketing and sale of compounded semaglutide drugs, Hims & Hers' shares dropped over 34% on June 23, 2025 [2]. - A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws [2]. Group 2: Legal Action - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to direct the case and advocate for other harmed investors [3].

Core Viewpoint - A securities class action lawsuit has been filed against Civitas Resources, Inc. for failing to disclose significant production reductions and operational challenges during the Class Period from February 27, 2024, to February 24, 2025 [1][3]. Company Overview - Civitas Resources, Inc. is a crude oil and natural gas company headquartered in Denver [2]. Financial Performance - For Q4 and full-year 2024, Civitas reported revenue of $1.29 billion, missing consensus estimates by $3.44 million, and non-GAAP earnings per share of $1.78, which was $0.21 below expectations [4]. - The net income for the quarter was $151.1 million, or $1.57 per share, a decline from $302.9 million, or $3.23 per share, in the same quarter the previous year [4]. Operational Challenges - Civitas indicated that it is likely to significantly reduce oil production in 2025 due to natural declines after peak production in the DJ Basin in Q4 2024 [3]. - The company announced a 10% workforce reduction and the termination of its Chief Operating Officer and Chief Transformation Officer [5]. Market Reaction - Following the announcement of its financial results and operational outlook, Civitas's stock price fell by $8.95 per share, or 18%, closing at $40.35 per share on February 25, 2025 [6].

Core Viewpoint - A securities class action lawsuit has been filed against Open Lending Corporation for misrepresentation and failure to disclose significant financial issues during the class period from February 24, 2022, to March 31, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Open Lending securities during the specified class period [1][2]. - Investors have until June 30, 2025, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations Against the Company - The complaint alleges that Open Lending misrepresented its risk-based pricing models and profit share revenue [3]. - It is claimed that the company failed to disclose that its 2021 and 2022 vintage loans were worth significantly less than their outstanding balances [3]. - The underperformance of the company's 2023 and 2024 vintage loans was also misrepresented [3]. Group 3: Financial Disclosures and Impact - On March 17, 2025, Open Lending announced it would delay its Annual Report for 2024, leading to a 9% drop in share price to $3.91 [4]. - The company reported a quarterly revenue of negative $56.9 million for Q4 2024, attributed to an $81.3 million reduction in estimated profit share revenues due to heightened delinquencies and defaults [5]. - The share price fell by 57% to $1.17 on April 1, 2025, following the financial disclosures [6].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for alleged misrepresentation regarding its capital allocation priorities following the acquisition of Dermavant [1][3]. Company Overview - Organon & Co. is a healthcare company focused on women's health, headquartered in Jersey City, NJ [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3]. - The suit alleges that after the acquisition, Organon shifted its capital allocation focus to debt reduction instead of maintaining dividend payouts [3]. Dividend Announcement - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 per share to $0.02 per share, stating that returning capital to shareholders was a lower priority [4]. - Following this announcement, Organon's stock price fell by $3.48 per share, approximately 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Civitas Resources, Inc. for failing to disclose significant operational challenges during the Class Period from February 27, 2024, to February 24, 2025 [1][3]. Group 1: Company Performance - Civitas reported Q4 and full-year 2024 financial results with revenue of $1.29 billion, missing consensus estimates by $3.44 million, and non-GAAP earnings per share of $1.78, missing estimates by $0.21 per share [4]. - The company’s net income for Q4 2024 was $151.1 million, or $1.57 per share, a decline from $302.9 million, or $3.23 per share, in the same quarter the previous year [4]. Group 2: Operational Challenges - The lawsuit claims that Civitas was likely to significantly reduce its oil production in 2025 due to declines after reaching peak production in the DJ Basin in Q4 2024 [3]. - Civitas indicated that increasing oil production would necessitate acquiring additional acreage and implementing disruptive cost-reduction measures [3]. Group 3: Workforce and Management Changes - Civitas announced a 10% reduction in its workforce across all levels as part of its 2025 outlook [5]. - The company terminated its Chief Operating Officer Hodge Walker and Chief Transformation Officer Jerome Kelly [5]. Group 4: Market Reaction - Following the announcement of its financial results and operational outlook, Civitas's stock price fell by $8.95 per share, or 18%, closing at $40.35 per share on February 25, 2025 [6].

PHILADELPHIA, May 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired VIATRIS securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff represent ...

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI) on behalf of purchasers of Compass securities between May 1, 2024 through May 7, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Compass Diversified Holdings securities during the Class Period may, no later than JULY 8, 2025, seek to be appointed as ...

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation priorities following the acquisition of Dermavant [1][3]. Company Overview - Organon & Co. is a healthcare company focused on women's health, headquartered in Jersey City, NJ [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3]. - The suit alleges that after the acquisition, Organon shifted its focus to reducing debt rather than maintaining dividend payouts [3]. Stock Price Reaction - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 per share to $0.02 per share, stating that returning capital to shareholders was a lower priority [4]. - Following this announcement, Organon's stock price fell by $3.48 per share, approximately 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4].

PHILADELPHIA, May 28, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against VIATRIS INC. ("Viatris" or the "Company") (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Viatris securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff representative ...

Core Viewpoint - A securities class action lawsuit has been filed against Compass Diversified Holdings for failing to disclose significant accounting irregularities related to its acquisition of Lugano Holdings, impacting the financial reporting during the Class Period from May 1, 2024, to May 7, 2025 [1][3]. Company Overview - Compass Diversified Holdings is a private equity firm headquartered in Westport, Connecticut, which acquired a majority interest in Lugano Holdings, Inc., a high-end jewelry designer, in a deal valued at $256 million in 2021 [2]. Legal Allegations - The lawsuit alleges that Compass did not disclose that Lugano violated accounting rules and industry practices during fiscal 2024, leading to distorted financial results due to these irregularities [3]. - It is also claimed that Compass failed to implement effective internal controls over its financial reporting [3]. Investor Information - Investors who purchased Compass securities during the Class Period have until July 8, 2025, to seek appointment as a lead plaintiff representative of the class [2].